Encouraging News On The Immunotherapy Front
June 22, 2020
FDA has now approved KEYTRUDA (pembrolizumab) for a second indication based on a tumor biomarker rather than the originating source of the tumor in the body. Specifically, FDA has approved KEYTRUDA for patients with an unresectable or metastatic solid tumor with a high mutational burden (i.e, 10 or more mutations). As part of this approval, FDA has also approved Foundation...